Pipeline


Product
Potential Indications
Preclinical
Phase 1
Phase 2
Phase 3
NGM282 (aldafermin)
FGF19 Analog
NASH
NGM313 (MK-3655)
FGFR1c/KLB Agonistic Antibody
NASH, Type 2 Diabetes
NGM120
GFRAL Antagonistic Antibody
Cancer Anorexia / Cachexia Syndrome
NGM217
Undisclosed
Diabetes
NGM621
Undisclosed
Dry Age-Related Macular Degeneration
NGM386
GDF15 Analog
Metabolic
NGM395
GDF15 Analog
Metabolic